Treatment of Aspirin-Resistant Patients With Omega-3 Fatty Acids Versus Aspirin Dose Escalation

Journal of the American College of Cardiology

Volumn 55, Issue 2, 2010, Pages 114-121

  Lev, Eli I ^a,b   Solodky, Alejandro ^a,b   Harel, Naama ^a   Mager, Aviv ^a,b   Brosh, David ^a,b   Assali, Abid ^a,b   Roller, Milton ^a,b   Battler, Alexander ^a,b   Kleiman, Neal S ^c   Kornowski, Ran ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

aspirin; omega 3 fatty acids; platelets

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID PLUS DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA MAX 3; THROMBOXANE B2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASSAY; BELCHING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LOW DRUG DOSE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

AGED; ASPIRIN; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; TREATMENT OUTCOME;

EID: 73049109353     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.08.039     Document Type: Article

References (30)

1. Buchanan M.R., and Brister S.J. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 11 (1995) 221-227
2. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
3. Gum P.A., Kottke-Marchant K., Poggio E.D., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
4. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
5. Lev E.I., Patel R., Maresh K., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Col Cardiol 47 (2006) 27-33
6. Chen W.H., Lee P.Y., Ng W., Tse H.F., and Lau C.P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
7. Chen W.H., Chang X., Lee P.Y., et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 120 (2007) 631-635
8. Tantry U.S., Bliden K.P., and Gurbel P.A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46 (2005) 1705-1709
9. Eikelboom J.W., Hankey G.J., Thom J., et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 118 (2008) 1705-1712
10. Krasopoulos G., Brister S.J., Beattie W.S., and Buchanan M.R. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336 (2008) 195-198
11. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G., and Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167 (2007) 1593-1599
12. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
13. Lee P.Y., Chen W.H., Ng W., et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 118 (2005) 723-727
14. Gurbel P.A., Bliden K.P., DiChiara J., et al. Evaluation of dose-related effects of aspirin on platelet function results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115 (2007) 3156-3164
15. Smith W.L. Cyclooxygenases, peroxide tone and the allure of fish oil. Curr Opin Cell Biol 17 (2005) 174-182
16. Engler M.M., and Engler M.B. Omega-3 fatty acids: role in cardiovascular health and disease. J Cardiovasc Nurs 21 (2006) 17-24
17. Knapp H.R. Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr 65 (1997) 1687S-1698S
18. Mori T.A., Beilin L.J., Burke V., Morris J., and Ritchie J. Interactions between dietary fat, fish and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 17 (1997) 279-286
19. Larson M.K., Ashmore J.H., Harris K.A., et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost 100 (2008) 634-641
20. Harris W.S. Expert opinion: omega-3 fatty acids and bleeding-cause for concern?. Am J Cardiol 99 (2007) 44C-46C
21. Eritsland J., Arnesen H., Gronseth K., Fjeld N.B., and Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 77 (1996) 31-36
22. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
23. Patrono C., Coller B., FitzGerald G.A., Hirsh J., and Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 Suppl (2004) 234S-264S
24. Maree A.O., and Fitzgerald D.J. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 115 (2007) 2196-2207
25. Hart R.G., Leonard A.D., Talbert R.L., et al. Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy 23 (2003) 579-584
26. Gasparyan A.Y., Watson T., and Lip G.Y. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 51 (2008) 1829-1843
27. Guthikonda S., Lev E.I., Patel R., et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 5 (2007) 490-496
28. Engström K., Wallin R., and Saldeen T. Effect of low-dose aspirin in combination with stable fish oil on whole blood production of eicosanoids. Prostaglandins Leukot Essent Fatty Acids 64 (2001) 291-297
29. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999) 447-455
30. von Schacky C., Angerer P., Kothny W., et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 130 (1999) 554-562